Evidence map›Paper›PMID 42875463›Full record

ArticleNature communications2026

Chromatin modifiers KMT2D, cBAF, and p300 cooperatively facilitate de novo binding of transcription factors on enhancers.

Hieu T Van, Young-Kwon Park, Danyang Wan, Chengyu Liu, Shamima Islam, Stefania Dell'Orso, Weiqun Peng, Vittorio Sartorelli, Ji-Eun Lee, Kai Ge

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Chill factor.Nature structural & molecular biology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Hieu T VanNational Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health (NIH), Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-3328-915X
Young-Kwon ParkNational Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health (NIH), Bethesda, MD, USA.
Danyang WanNational Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health (NIH), Bethesda, MD, USA.ORCID http://orcid.org/0000-0001-8278-3616
Chengyu LiuTransgenic Core, National Heart, Lung, and Blood Institute, NIH, Bethesda, MD, USA.
Shamima IslamGenome Technology Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH, Bethesda, MD, USA.
Stefania Dell'OrsoGenome Technology Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-1306-2820
Weiqun PengDepartment of Physics and Department of Anatomy and Cell Biology, The George Washington University, Washington, DC, USA.ORCID http://orcid.org/0000-0001-5521-9091
Vittorio SartorelliLaboratory of Muscle Stem Cells and Gene Regulation, NIAMS, NIH, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-9284-3675
Ji-Eun LeeNational Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health (NIH), Bethesda, MD, USA. leejieun@niddk.nih.gov.ORCID http://orcid.org/0000-0002-3768-7016
Kai GeNational Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health (NIH), Bethesda, MD, USA. KaiGeLab@outlook.com.ORCID http://orcid.org/0000-0002-7442-5138

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Transcription factors (TFs) bind to enhancers and recruit H3K4me1 methyltransferase KMT2D, chromatin remodeler cBAF, and H3K27 acetyltransferase p300 to activate transcription. However, the role of chromatin modifiers in regulating de novo binding of TFs on enhancers remains unclear. Using a robust nuclear translocation system, we show that the muscle lineage-determining TF MyoD binds to chromatin pervasively within one hour, with half of induced MyoD binding sites co-occupied by KMT2D, cBAF, and p300. On the majority of these MyoD

Indexed as

ChromatinDNA-Binding ProteinsE1A-Associated p300 ProteinEnhancer Elements, GeneticTranscription FactorsAnimalsBinding SitesHistone-Lysine N-MethyltransferaseMiceMyeloid-Lymphoid Leukemia ProteinMyoD ProteinProtein BindingReceptors, GlucocorticoidChromatinDNA-Binding ProteinsE1A-Associated p300 ProteinEp300 protein, mouseHistone-Lysine N-MethyltransferaseKmt2d protein, mouseMyeloid-Lymphoid Leukemia ProteinMyoD1 myogenic differentiation proteinMyoD ProteinReceptors, GlucocorticoidTranscription Factors

Identifiers

PMID42875463
PMCPMC13669397

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.